- Home
- Automated
- List of product information
- IOPAMIRO 370 INJECTION 7.55 G/10 ML [SIN05907P]
IOPAMIRO 370 INJECTION 7.55 G/10 ML [SIN05907P]
Active ingredients: IOPAMIRO 370 INJECTION 7.55 G/10 ML
Last updated 26 October 2025
Product Info
IOPAMIRO 370 INJECTION 7.55 G/10 ML
[SIN05907P]
Product information
Active Ingredient and Strength | IOPAMIDOL - 7.55 G/10 ML |
Dosage Form | INJECTION |
Manufacturer and Country | PATHEON ITALIA S.P.A - ITALY |
Registration Number | SIN05907P |
Licence Holder | DCH AURIGA SINGAPORE |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | V08AB04 |
INDICATIONS
NEURORADIOLOGY: myeloradiculography, cisternography and ventriculography.
ANGIOGRAPHY: cerebral arteriography, coronary arteriography, thoracic aortography, abdominal aortography, angiocardiography, selective visceral arteriography, peripheral arteriography, venography, digital subtraction angiography (DSA), DSA of cerebral arteries, DSA of peripheral arteries, DSA of abdominal arteries.
UROGRAPHY: intravenous urography.
CONTRAST ENHANCEMENT IN CT SCANNING. ARTHROGRAPHY. FISTULOGRAPHY.
NEURORADIOLOGY
ANGIOGRAPHY
UROGRAPHY
Iopamiro 300 and 370 should be used; the dose recommended for this type of examination is 30 to 50 ml.
The less marked osmotic diuresis induced by the nonionic agent makes Iopamiro 370 especially suitable for patients with mild or moderately severe renal insufficiency and for neonates. The new contrast medium affords diagnostically useful nephrography even in patients with major renal insufficiency.
OTHER DIAGNOSTIC PROCEDURES
For the enhancement of contrast in CT scans Iopamiro may be injected intravenously as a bolus, as a drip infusion or by a combination of the two methods.
CONTRAINDICATIONS
There are no definite or absolute contraindications to the use of Iopamiro, with the possible exception of Waldenström's macroglobulinemia, multiple myeloma, and severe liver and kidney diseases.